HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KRN 4884

structure given in first source

Also Known As:

5-amino-N-(2-(2-chlorophenyl)ethyl)-N'-cyano-3-pyridinecarboxamidine; KRN-4884; KRN4884

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - KRN 4884: 7

Experts

1.	Floten, H Storm: 1 article (07/2002)
2.	He, Guo-Wei: 1 article (07/2002)
3.	Ren, Zhen: 1 article (07/2002)
4.	Yang, Qin: 1 article (07/2002)
5.	Floten, H S: 1 article (02/2001)
6.	Furnary, A P: 1 article (02/2001)
7.	He, G W: 1 article (02/2001)
8.	Ren, Z: 1 article (02/2001)
9.	Yang, Q: 1 article (02/2001)
10.	Yim, A P: 1 article (02/2001)

Related Diseases

1.	Glucose Intolerance 02/01/2000 - "Treatment with KRN4884 (1.0 mg/kg, twice a day for 14 days, p.o.) improved the glucose intolerance and inhibited hypersecretion of insulin in the glucose-loaded, fructose-fed rats. "
2.	Insulin Resistance 02/01/2000 - "These findings suggested that KRN4884 enhances insulin sensitivity and LPL activity, which are related to glucose and lipid metabolism and may be useful for the treatment of syndrome X."
3.	Hypertension (High Blood Pressure) 02/01/1999 - "The 7-day repeated administration of KRN4884 (0.5, 1.5 mg/kg, p.o.) did not diminish antihypertensive activity during the treatment period or induce rebound hypertension after the discontinuation of treatment. " 02/01/2000 - "High-fructose diet rats developed hypertension, hypertriglyceridemia, increased total cholesterol/HDL (high-density lipoprotein)-cholesterol ratio, and hyperinsulinemia, KRN4884 (0.3-3.0 mg/kg, twice a day for 14 days, p.o.) alleviated the risk factors in fructose-fed rats. "
4.	Hypoxia (Hypoxemia) 07/01/2002 - "Porcine coronary microartery rings (diameter 200 to 500 microm) studied in a myograph were divided into seven groups: (1) control group; (2) hypoxia-reoxygenation group (hypoxia for 60 minutes followed by reoxygenation for 30 minutes); (3) preconditioning group (hypoxia for 5 minutes followed by reoxygenation for 10 minutes before hypoxia reoxygenation); (4) KRN4884 pretreatment group (KRN4884 was added into the myograph chamber 20 minutes before hypoxia reoxygenation); (5) 5-hydroxydecanoate + KRN group (5-hydroxydecanoate was given 20 minutes before KRN4884 pretreatetment); (6) glibenclamide (GBC) + KRN group (GBC was added 20 minutes before KRN4884 pretreatment); and (7) endothelium denuded group (the endothelium was removed). " 02/01/2001 - "In the organ chamber, porcine coronary artery rings (n = 96) were studied in 6 groups (n = 16 in each group): I. normoxia (pO2 > 200 mmHg); II. Hypoxia-reoxygenation: 60-minute hypoxia (pO2 < 15 mmHg) followed by 30-minute reoxygenation; III. Preconditioning: 5-minute hypoxia followed by 10-minute reoxygenation prior to hypoxia-reoxygenation; IV. KRN4884-pretreatment: KRN4884 (30 microM) was added into the chamber 20 minutes before hypoxia-reoxygenation; V. 5-HD-pretreatment: sodium 5-hydroxydecanoate (5-HD, 10 microM) was given 20 minutes prior to KRN4884-pretreatment; and VI. GBC-pretreatment: glibenclamide (GBC, 3 microM) was added 20 minutes prior to KRN4884-pretreatment. "
5.	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/01/2000 - "Effects of the K+ channel opener KRN4884 on the cardiovascular metabolic syndrome model in rats." 02/01/2000 - "We examined the effects of the potassium channel opener KRN4884 (5-amino-N-[2-(2-chlorophenyl)ethyl]-N'-cyano-3-pyridinecarboxamidine ) on cardiovascular metabolic syndrome (i.e., syndrome X), in rats. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Glucose (Dextrose)
3.	Fructose
4.	nilvadipine (Escor)
5.	Cromakalim (Levcromakalim)
6.	Potassium Channels (Potassium Channel)
7.	Glyburide (Glibenclamide)
8.	5-hydroxydecanoic acid
9.	Propranolol (Inderal)
10.	HDL Cholesterol

Related Therapies and Procedures

1.	Therapeutics